| HOME >> BIOLOGY >> TECHNOLOGY |
MOUNTAIN VIEW, Calif., May 19 /PRNewswire/ -- ChemoCentryx, Inc., today announced that Thomas J. Schall, Ph.D., the Company's President and Chief Executive Officer is a finalist for the Ernst & Young Entrepreneur Of The Year® 2010 Award in Northern California. According to Ernst & Young LLP, the awards program recognizes entrepreneurs who demonstrate extraordinary success in the areas of innovation, financial performance and personal commitment to their businesses and communities. Dr. Schall was selected as a finalist from over 100 nominations by a panel of independent judges. Award recipients will be announced at a special gala event on June 12, 2010, at the San Jose Fairmont Hotel.
Dr. Schall is being recognized for his role in founding and leading ChemoCentryx, a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine and chemoattractant systems in order to treat autoimmune diseases, inflammatory disorders and cancer. As one of the earliest investigators in the field of chemokine biology, Dr. Schall and his team at ChemoCentryx have successfully established one of the broadest pipelines of chemokine-based therapeutics in the pharmaceutical industry, with five products now in clinical development.
"I am honored to be included in such a prestigious program," said Thomas J. Schall, Ph.D., President and Chief Executive Officer of ChemoCentryx. "It has been an extremely rewarding experience to work with this gifted ChemoCentryx team to build the Company and help bring us closer to providing valuable new treatment options for patients who suffer from autoimmune and
'/>"/>
| SOURCE ChemoCentryx, Inc. Copyright©2010 PR Newswire. All rights reserved |